Last reviewed · How we verify
Topical CA
At a glance
| Generic name | Topical CA |
|---|---|
| Also known as | Centella asiatica ointment |
| Sponsor | Indonesia University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Treatment of Hypertrophic Scars Using Fractional CO2 Laser Alone in Comparison With Adding Botulinum Toxin Either Through Intralesional Injection or Assisted Drug Delivery (NA)
- A Randomized Clinical Trial to Prevent Recurrent CA-MRSA Infection (PHASE3)
- Neodymium-doped Yttrium Aluminum Garnet (Nd:YAG) Laser Treatment for Granular Corneal Dystrophy (NA)
- Characterization of the Toll-like Receptor 7-agonist Imiquimod 3.75% As a New Surrogate Model of Itch (NA)
- The Efficacy of Botulinum Toxin Alone Versus Combined Botulinum Toxin and Topical Diltiazem in Chronic Anal Fissure
- Topical Interferon Gamma-1b for Central Serous Chorioretinopathy (PHASE1, PHASE2)
- Blue Light Therapy of C. Acnes (PHASE4)
- Topical Centella Asiatica and the Cosmetic Appearance of Stretch Marks (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical CA CI brief — competitive landscape report
- Topical CA updates RSS · CI watch RSS
- Indonesia University portfolio CI